Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)
Status:
Terminated
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this first in human and proof of concept study is to characterize the safety,
tolerability and initial efficacy of CLL442 in patients with Squamous Cell Carcinoma in situ
(SCCis) to enable further clinical development of CLL442.